The use of genes for performance enhancement: doping or therapy?

R. S. Oliveira, T. F. Collares, Kevin R. Smith, T. V. Collares, F. K. Seixas

Research output: Contribution to journalArticle

  • 9 Citations

Abstract

Recent biotechnological advances have permitted the manipulation of genetic sequences to treat several diseases in a process called gene therapy. However, the advance of gene therapy has opened the door to the possibility of using genetic manipulation (GM) to enhance athletic performance. In such ‘gene doping’, exogenous genetic sequences are inserted into a specific tissue, altering cellular gene activity or leading to the expression of a protein product. The exogenous genes most likely to be utilized for gene doping include erythropoietin (EPO), vascular endothelial growth factor (VEGF), insulin-like growth factor type 1 (IGF-1), myostatin antagonists, and endorphin. However, many other genes could also be used, such as those involved in glucose metabolic pathways. Because gene doping would be very difficult to detect, it is inherently very attractive for those involved in sports who are prepared to cheat. Moreover, the field of gene therapy is constantly and rapidly progressing, and this is likely to generate many new possibilities for gene doping. Thus, as part of the general fight against all forms of doping, it will be necessary to develop and continually improve means of detecting exogenous gene sequences (or their products) in athletes. Nevertheless, some bioethicists have argued for a liberal approach to gene doping.
Original languageEnglish
Pages (from-to)1194-1201
Number of pages8
JournalBrazilian Journal of Medical and Biological Research
Volume44
Issue number12
DOIs
StatePublished - Dec 2011

Fingerprint

Genes
Cyclic AMP Receptor Protein
Genetic Therapy
Gene therapy
Myostatin
Ethicists
Endorphins
Athletic Performance
Somatomedins
Erythropoietin
Metabolic Networks and Pathways
Athletes
Vascular Endothelial Growth Factor A
Sports
Glucose
Proteins
Library Catalogs
Anal Sacs
Supravalvular Aortic Stenosis
Switzerland

Cite this

Oliveira, R. S.; Collares, T. F.; Smith, Kevin R.; Collares, T. V.; Seixas, F. K. / The use of genes for performance enhancement: doping or therapy?

In: Brazilian Journal of Medical and Biological Research, Vol. 44, No. 12, 12.2011, p. 1194-1201.

Research output: Contribution to journalArticle

@article{17d60e9f07404df09db0bf60c2f66190,
title = "The use of genes for performance enhancement: doping or therapy?",
abstract = "Recent biotechnological advances have permitted the manipulation of genetic sequences to treat several diseases in a process called gene therapy. However, the advance of gene therapy has opened the door to the possibility of using genetic manipulation (GM) to enhance athletic performance. In such ‘gene doping’, exogenous genetic sequences are inserted into a specific tissue, altering cellular gene activity or leading to the expression of a protein product. The exogenous genes most likely to be utilized for gene doping include erythropoietin (EPO), vascular endothelial growth factor (VEGF), insulin-like growth factor type 1 (IGF-1), myostatin antagonists, and endorphin. However, many other genes could also be used, such as those involved in glucose metabolic pathways. Because gene doping would be very difficult to detect, it is inherently very attractive for those involved in sports who are prepared to cheat. Moreover, the field of gene therapy is constantly and rapidly progressing, and this is likely to generate many new possibilities for gene doping. Thus, as part of the general fight against all forms of doping, it will be necessary to develop and continually improve means of detecting exogenous gene sequences (or their products) in athletes. Nevertheless, some bioethicists have argued for a liberal approach to gene doping.",
author = "Oliveira, {R. S.} and Collares, {T. F.} and Smith, {Kevin R.} and Collares, {T. V.} and Seixas, {F. K.}",
year = "2011",
month = "12",
doi = "10.1590/S0100-879X2011007500145",
volume = "44",
pages = "1194--1201",
journal = "Brazilian Journal of Medical and Biological Research",
issn = "0100-879X",
publisher = "Associacao Brasileira de Divulgacao Cientifica",
number = "12",

}

The use of genes for performance enhancement: doping or therapy? / Oliveira, R. S.; Collares, T. F.; Smith, Kevin R.; Collares, T. V.; Seixas, F. K.

In: Brazilian Journal of Medical and Biological Research, Vol. 44, No. 12, 12.2011, p. 1194-1201.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The use of genes for performance enhancement: doping or therapy?

AU - Oliveira,R. S.

AU - Collares,T. F.

AU - Smith,Kevin R.

AU - Collares,T. V.

AU - Seixas,F. K.

PY - 2011/12

Y1 - 2011/12

N2 - Recent biotechnological advances have permitted the manipulation of genetic sequences to treat several diseases in a process called gene therapy. However, the advance of gene therapy has opened the door to the possibility of using genetic manipulation (GM) to enhance athletic performance. In such ‘gene doping’, exogenous genetic sequences are inserted into a specific tissue, altering cellular gene activity or leading to the expression of a protein product. The exogenous genes most likely to be utilized for gene doping include erythropoietin (EPO), vascular endothelial growth factor (VEGF), insulin-like growth factor type 1 (IGF-1), myostatin antagonists, and endorphin. However, many other genes could also be used, such as those involved in glucose metabolic pathways. Because gene doping would be very difficult to detect, it is inherently very attractive for those involved in sports who are prepared to cheat. Moreover, the field of gene therapy is constantly and rapidly progressing, and this is likely to generate many new possibilities for gene doping. Thus, as part of the general fight against all forms of doping, it will be necessary to develop and continually improve means of detecting exogenous gene sequences (or their products) in athletes. Nevertheless, some bioethicists have argued for a liberal approach to gene doping.

AB - Recent biotechnological advances have permitted the manipulation of genetic sequences to treat several diseases in a process called gene therapy. However, the advance of gene therapy has opened the door to the possibility of using genetic manipulation (GM) to enhance athletic performance. In such ‘gene doping’, exogenous genetic sequences are inserted into a specific tissue, altering cellular gene activity or leading to the expression of a protein product. The exogenous genes most likely to be utilized for gene doping include erythropoietin (EPO), vascular endothelial growth factor (VEGF), insulin-like growth factor type 1 (IGF-1), myostatin antagonists, and endorphin. However, many other genes could also be used, such as those involved in glucose metabolic pathways. Because gene doping would be very difficult to detect, it is inherently very attractive for those involved in sports who are prepared to cheat. Moreover, the field of gene therapy is constantly and rapidly progressing, and this is likely to generate many new possibilities for gene doping. Thus, as part of the general fight against all forms of doping, it will be necessary to develop and continually improve means of detecting exogenous gene sequences (or their products) in athletes. Nevertheless, some bioethicists have argued for a liberal approach to gene doping.

U2 - 10.1590/S0100-879X2011007500145

DO - 10.1590/S0100-879X2011007500145

M3 - Article

VL - 44

SP - 1194

EP - 1201

JO - Brazilian Journal of Medical and Biological Research

T2 - Brazilian Journal of Medical and Biological Research

JF - Brazilian Journal of Medical and Biological Research

SN - 0100-879X

IS - 12

ER -